Year Founded
2016
Ownership
Private
Employees
~10
Therapeutic Areas
Rare DiseasesInfectious DiseasesOncology
Stage
Preclinical
Modalities
Small molecule

A2A Pharma General Information

AI-driven drug design company developing novel therapeutics for multiple indications. Notable spin-off Biomea Fusion focused on MLL-Menin program raised $55M.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to A2A Pharma's pipeline data

Book a demo

Key Partnerships

Daewoong Pharmaceutical, Insilico Medicine, Laxai, Novartis, Procter & Gamble, Johnson & Johnson

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

A2A Pharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view A2A Pharma's complete valuation and funding history, request access »

A2A Pharma Investors

SOSV
Investor Type: Venture Capital
Holding: Minority
IndieBio
Investor Type: Venture Capital
Holding: Minority
JLabs
Investor Type: Venture Capital
Holding: Minority